ERBB2 and ovarian cancer: Intratumoral injection of HER2-CD3-Fc mRNA-LNPs triggers a strong antitumor response against HER2-positive tumors and completely blocks the A1847 ovarian cancer xenograft tumors in vivo without showing any signs of toxic effects.